When was Atreca founded?

Atreca was founded in 2010 and raised its 1st funding round 1 year after it was founded.

Where is Atreca located?

Atreca is headquartered in San Carlos, United States. It is registered at 835 Industrial Rd., Suite 400 San Carlos, CA 94070 United States.

How many employees does Atreca have?

As of Sep 30, 2026, the latest employee count at Atreca is 18.

Is Atreca a funded company?

Atreca is a funded company, having raised a total of $224M across 9 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Nov 11, 2011.

When was the latest funding round of Atreca?

Atreca's latest funding was a $***** Series C round on Sep 12, 2018, with participation from 7 investors.

Where does Atreca rank among its competitors?

Atreca ranks 1027th amongst 3330 active competitors, of which 1129 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Atreca?

Atreca's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Atreca - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of antibody therapeutics for human anti-cancer immune responses. The company uses proprietary Immune Repertoire Capture (IRC) technology to analyze patient immune responses for improved clinical outcomes in cancer treatments.

Website: atreca.com
Registered Address: 835 Industrial Rd., Suite 400 San Carlos, CA 94070 United States

Key Metrics

Founded Year

2010

Location

San Carlos, United States

Stage

Public

Total Funding

$224M in 9 rounds

Latest Funding Round

Series C, Sep 12, 2018, $*****

Investors

Gates & 15 more

Ranked

1027^th among 3330 active competitors

Employee Count

18 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3051 more

Exit Details

Public

View Atreca's full profile

Atreca is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Atreca, Inc. CIN: 27-3723255 , United States, Active	Jun 10, 2010	-	138 (As on Dec 31, 2021)	-

Atreca got listed on Jun 20, 2019.

Click here to take a look at Atreca's IPO in detail

Atreca has raised a total funding of $224M over 9 rounds. Its first funding round was on Nov 11, 2011. Its latest funding round was a Series C round on Sep 12, 2018 for $*****. 7 investors participated in its latest round. Atreca has 16 institutional investors.

Here is the list of recent funding rounds of Atreca:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 12, 2018	8532800	Series C	9034590	9655892	1807315	6383019
Aug 17, 2017	7517314	Series B	8394973	7567959	4113514	8815772
Oct 2015	9129866	Series A	3010776	2063380	Gates & 2 more	6451948

Access funding benchmarks and valuations. Sign up today!

View details of Atreca's funding rounds and investors

Atreca's employee count trend

Atreca has 18 employees as of Sep 26. Here is Atreca's employee count trend over the years:

Uncover Atreca's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Atreca include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Atreca, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, Khosla Ventures & 23 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
1027th	Atreca 2010, San Carlos (United States), Public	Developer of antibody therapeutics for human anti-cancer immune responses	$224M	Boxer Capital, Redmile Group & 14 others	40/100